Finally, in patients with CAD, P2Y12 inhibitor monotherapy was associated with a lower risk of cardiovascular death, MI, and stroke compared with aspirin monotherapy [5,6,49,50,56,69]. This evidence concerns the gene P2RY12 and coronary artery disorder.